Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen Inc. (OCGN) is a clinical-stage biopharmaceutical company pioneering gene therapies for retinal diseases and innovative vaccine platforms. This dedicated news hub provides investors and researchers with timely updates on Ocugen’s scientific advancements, regulatory milestones, and strategic initiatives.
Access verified press releases and curated financial news covering clinical trial developments, partnership announcements, and corporate updates. Our repository includes updates on modifier gene therapy programs for conditions like retinitis pigmentosa, inhaled vaccine research, and ocular disorder treatments undergoing regulatory review.
Key content categories include progress reports on Phase I-III trials, FDA designations, intellectual property updates, and financial performance summaries. Bookmark this page for streamlined tracking of OCGN’s advancements in gene editing technologies and mucosal vaccine development.
Ocugen, Inc. (NASDAQ: OCGN) announces that Dr. Shankar Musunuri, Chairman and CEO, will present at the 34th Annual Roth Conference on March 14, 2022, at 11:00 AM PT in Dana Point, CA. The event will feature meetings, analyst chats, and industry panels from approximately 400 companies. Ocugen focuses on gene therapies for retinal diseases and co-develops the COVID-19 vaccine candidate COVAXIN™. A live audio webcast of the presentation will be available on the company’s investor relations website.
Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA has declined to issue an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate, COVAXIN™, for individuals aged 2 to 18. The company plans to collaborate with the FDA to explore regulatory pathways for pediatric use. Ocugen is dedicated to developing gene therapies for blindness diseases and furthering its vaccine initiative. The ongoing efforts reflect Ocugen's commitment to advancing solutions in both ocular diseases and infectious diseases.
Ocugen reported significant progress in its COVAXIN™ development, with the FDA lifting the clinical hold on its IND application, enabling the commencement of Phase 2/3 trials. The company submitted a substantial safety database involving over 36 million vaccinated teens to support its pediatric EUA request. Additionally, Ocugen initiated a Phase 1/2 trial for its OCU400 gene therapy. Despite increased R&D and administrative expenses, cash reserves expanded to $95.1 million. The company announced a public offering of 16 million shares to further support its development pipeline.
Ocugen, Inc. (Nasdaq: OCGN) announced a public offering of approximately 15.97 million shares of common stock, priced for gross proceeds of about $53.5 million. The offering is set to close on or about February 25, 2022. An additional 2.39 million shares may be purchased by the underwriter within 30 days. Proceeds will be used for corporate purposes, including working capital. Cantor Fitzgerald & Co. is the sole book-running manager for this offering, which is conducted under a previously filed shelf registration with the SEC.
Ocugen, Inc. (Nasdaq: OCGN) has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase an additional 15% of shares. The proceeds will be utilized for general corporate necessities, including capital expenditures and working capital. The offering is contingent upon market conditions and other customary closing prerequisites, with no assurance of completion or specific terms. Cantor Fitzgerald & Co. serves as the sole book-running manager. The offering is registered under a previously filed shelf registration statement.
Ocugen, Inc. (NASDAQ: OCGN) announced a conference call scheduled for February 25, 2022, at 8:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. A pre-market earnings announcement will be issued on the same day. Investors can participate via a toll-free dial-in number and a webcast. Ocugen focuses on gene therapies for blindness and co-developing Bharat Biotech’s COVAXIN™ vaccine for COVID-19. The company emphasizes its innovation in treating retinal diseases and seeks to provide updates on its business and financial performance.
Ocugen, Inc. (NASDAQ: OCGN) announced that the FDA has lifted the clinical hold on its IND application to evaluate the COVID-19 vaccine candidate COVAXIN™ (BBV152). COVAXIN™ is a whole-virion inactivated vaccine developed by Bharat Biotech and has been administered in over 200 million doses worldwide. It’s authorized for emergency use in 20 countries, with pending applications in more than 60 others. Ocugen aims to provide an alternative COVID-19 vaccine, emphasizing the importance of diverse approaches to pandemic management.
Ocugen's recent survey, conducted by The Harris Poll, reveals strong public interest in alternative COVID-19 vaccines developed through traditional methods. Key findings indicate that 73% of Americans prefer more conventional vaccine options, and 40% of unvaccinated parents would consider vaccinating their children if a new, more traditional vaccine were available. Additionally, 38% of parents with children under 5 are hesitant about existing vaccines. This data highlights the demand for diverse vaccine options amidst ongoing discussions about childhood vaccinations.
Ocugen has signed a non-binding letter of intent to acquire a dormant vaccine manufacturing site in Belleville, Ontario from Liminal BioSciences. This facility aims to enhance Ocugen's manufacturing and R&D capabilities, particularly for its COVID-19 vaccine candidate, COVAXIN™ (BBV152). The renovated site will serve as a hub for breakthrough gene therapies and is expected to stimulate regional economic growth and job creation in Ontario. The acquisition, however, is subject to due diligence and final agreements, with no assurance of completion.
Ocugen, Inc. (NASDAQ: OCGN) announces the appointment of Dr. Nirdosh Jagota as Senior Vice President of Regulatory Affairs. He brings 30 years of experience in the biopharmaceutical sector, previously serving at Arcturus Therapeutics and holding senior roles at major companies like Genentech and Pfizer. Dr. Jagota is tasked with overseeing regulatory strategies for Ocugen’s gene therapy and vaccine development. His extensive background includes the successful approval of over 30 vaccines and therapeutics. The company aims to enhance its regulatory capabilities and expedite product commercialization.
